Press Release on Q4FY26 Audited Financial Results
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma reported record revenues and profitability for Q4FY26 with consolidated revenue of ₹17,428 million, up 22% YoY. Full year FY26 revenue stood at ₹64,307 million, growing 14.5%. The company saw exceptional PAT growth with Q4 adj. PAT at ₹3,667 million (up 97% YoY) and FY26 adj. PAT at ₹10,455 million (up 50% YoY). EBITDA margin expanded significantly with Q4 adj. EBITDA margin at 30% (vs 24% in Q4FY25) and FY26 at 26% (vs 23% in FY25). CDMO business contributed 46% of revenues and grew 36% YoY in Q4FY26. The company launched 31 products in the US during FY26 and filed 24 ANDAs with 28 approvals. The Board recommended a final dividend of ₹20 per share. USA remains the largest market contributing ₹9,807 million in Q4.
Strong quarter with double-digit revenue growth and near-doubling of PAT demonstrates operational leverage and successful CDMO ramp-up. Margin expansion signals improving profitability and should be positive for the stock.